Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Global Clinical Trials Review, H1, 2014 - KHGI-TV/KWNB-TV/KHGI-CD-Grand Island, Kearney, Hastings

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Global Clinical Trials Review, H1, 2014

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Reportlinker

NEW YORK, June 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Global Clinical Trials Review, H1, 2014

http://www.reportlinker.com/p02133109/Mucopolysaccharidosis-I-MPS-I-Hurler-Syndrome-Global-Clinical-Trials-Review-H1-2014.html

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Global Clinical Trials Review, H1, 2014" provides data on the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Mucopolysaccharidosis I (MPS I) (Hurler Syndrome). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) to Metabolic Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) to Metabolic Disorders Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Unaccomplished Trials of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) 24
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) 31
Apr 20, 2012: Athersys Announces Publication Of Results Of Preclinical Study Of MultiStem In Cell Transplant 31
Clinical Trial Profiles 32
Clinical Trial Overview of Top Companies 32
Sanofi 32
Clinical Trial Overview of Sanofi 32
Medical Resources International Pte Ltd 33
Clinical Trial Overview of Medical Resources International Pte Ltd 33
Cytomedix, Inc. 34
Clinical Trial Overview of Cytomedix, Inc. 34
ArmaGen Technologies, Inc. 35
Clinical Trial Overview of ArmaGen Technologies, Inc. 35
Clinical Trial Overview of Top Institutes / Government 36
Masonic Cancer Center 36
Clinical Trial Overview of Masonic Cancer Center 36
University of Minnesota 37
Clinical Trial Overview of University of Minnesota 37
University of California, Los Angeles 38
Clinical Trial Overview of University of California, Los Angeles 38
New York Medical College 39
Clinical Trial Overview of New York Medical College 39
Tehran University of Medical Sciences 40
Clinical Trial Overview of Tehran University of Medical Sciences 40
Center for International Blood and Marrow Transplant Research 41
Clinical Trial Overview of Center for International Blood and Marrow Transplant Research 41
Erasmus MC 42
Clinical Trial Overview of Erasmus MC 42
The University of Chicago 43
Clinical Trial Overview of The University of Chicago 43
University of Louisville 44
Clinical Trial Overview of University of Louisville 44
Five Key Clinical Profiles 45
Appendix 72
Abbreviations 72
Definitions 72
Research Methodology 73
Secondary Research 73
About GlobalData 74
Contact Us 74
Disclaimer 74
Source 74

List of Tables
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials by Region, 2014* 7
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014* 15
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014* 18
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials by Phase, 2014* 20
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 21
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Suspended Clinical Trials, 2014* 24
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 32
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical Resources International Pte Ltd, 2014* 33
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Cytomedix, Inc., 2014* 34
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by ArmaGen Technologies, Inc., 2014* 35
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Masonic Cancer Center, 2014* 36
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Minnesota, 2014* 37
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, Los Angeles, 2014* 38
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by New York Medical College, 2014* 39
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 40
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Center for International Blood and Marrow Transplant Research, 2014* 41
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by Erasmus MC, 2014* 42
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Chicago, 2014* 43
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Louisville, 2014* 44

List of Figures
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2014* 15
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2014* 18
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 20
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 21
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30 
GlobalData Methodology 73

Companies Mentioned

To order this report: Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Global Clinical Trials Review, H1, 2014
http://www.reportlinker.com/p02133109/Mucopolysaccharidosis-I-MPS-I-Hurler-Syndrome-Global-Clinical-Trials-Review-H1-2014.html

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
General and news information or questions:
Across the Midlands Information:
events@nebraska.tv
Comments: comments@nebraska.tv
News:
news@nebraska.tv
Phone: 308-743-2494
News Fax: 308-743-2660
All content © Copyright 2000 - 2014 WorldNow and NTV. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.